medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2006, Número 4

<< Anterior Siguiente >>

Ann Hepatol 2006; 5 (4)


Efficacy of oral L-ornithine-L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy. Results of a randomized, lactulose-controlled study

Poo JL, Góngora J, Sánchez-Ávila F, Aguilar-Castillo S, García-Ramos G, Fernández-Zertuche M, Rodríguez-Fragoso L, Uribe M

Idioma: Ingles.
Referencias bibliográficas: 34
Paginas: 281-288
Archivo PDF: 80.01 Kb.


FRAGMENTO

Sin resumen


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Mas A. Hepatic encephalopathy: from pathophysiology to treatment. Digestion 2006; 73(Suppl. 1): 86-93.

  2. Shawcross D, Jalan R. Dispelling myths in the treatment of hepatic encephalopathy. Lancet 2005; 365: 431-33.

  3. Lizardi-Cervera J, Almeda P, Guevara L, Uribe M. Hepatic encephalopathy: a review. Ann Hepatol 2003; 2: 122-130.

  4. Kircheis G, Haussinger D. Management of hepatic encephalopathy. J Gastroenterol Hepatol 2002; 17: 260-267.

  5. Brusilow A. Hyperammonemic encephalopathy. Rev Mol Med 2002; 81(3): 240-9.

  6. Blei AT, Cordoba J. Hepatic encephalopathy. Am J Gastro 2001; 96(7): 1968-1975.

  7. Butterworth RF. Pathophysiology of hepatic encephalopathy: a new look at ammonia. Metab Brain Dis 2002; 17(4): 221-7.

  8. Bongaerts G, Severijnen R, Timmerman H. Effect of antibiotics, prebiotics and probiotics in treatment for hepatic encephalopathy. Med Hypotheses 2005; 64(1): 64-8.

  9. Paik YH, Kwan SL, Kwang-Hyub H, et al. Comparison of Rifaximin and Lactulose for the treatment of hepatic encephalopathy: A prospective randomized study. Yonsei Medical Journal 2005; 46(3): 399-407.

  10. 10 Mas A, Rodes J, Sunyer L, Rodrigo L, et al. Comparison of Rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double blind, double dummy, controlled clinical trial. Journal of Hepatology 2003; 38: 51-58.

  11. 11 Riordan S, Williams R. Treatment of hepatic encephalopathy. N Engl J Med 1997; 337: 473-479.

  12. Ferenci P, Herneth A, Steindl P. Newer approaches to therapy of hepatic encephalopathy. Semin Liver Dis 1996; 16: 329-38.

  13. Uribe M, Moran S, Poo JL, Mendez-Sanchez N, Guevara L, Garcia-Ramos G. Beneficial effect of carbohydrate maldigestion induced by a disaccharidase inhibitor in the treatment of chronic portal-systemic encephalopathy. A double-blind, randomized, controlled trial. Scandinavian Journal of Gastroenterology 1998; 33: 1099-1106.

  14. Bodil Als-Nielsen, Lise L Gluud, Christian Gluud. Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomized trials. 2004; 328: 1046.

  15. Häussinger D. Nitrogen metabolism in liver: structural and functional organization and physiological relevance. Biochem J 1990; 267: 281-290.

  16. Gebhardt R, Beckers G, Gaunitz F, et al. Treatment of cirrhotic rats with L-ornithine-L-aspartate enhances urea synthesis and lowers serum ammonia levels. J Pharmacol Exp Ther 1997; 283(1): 1-6.

  17. Rose C, Michalak A, Pannunzio P, Therrien G, Quack G, Kircheis G, Butterworth RF. L-ornithine-L-aspartate in experimental portal-systemic encephalopathy: therapeutic efficacy and mechanism of action. Metab Brain Dis 1998; 13(2): 147-57.

  18. Rose C, Michalak A, Rao V, et al. L-ornithine-L-aspartate lowers plasma and cerebrospinal fluid ammonia and prevents brain edema in rats with acute liver failure. Hepatol 1999; 30(3): 636-40.

  19. Kircheis G, Wettstein M, Dahl S, Haussinger D. Clinical efficacy of L-ornithine-L-aspartate in the management of hepatic encephalopathy. Metab Brain Dis 2002; 17(4): 453-62.

  20. Pannunzio P, Rose C, Michalak A, et al. L-ornithine-L-aspartein experimental portosystemic encephalopathy: therapeutic efficacy and mechanism of action. J Neurochem 1998; 70(Suppl. 1): S64.

  21. Kircheis G, Nilius R, Held C. Therapeutic efficacy of L-ornithine-L-aspartate infusions in cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double blind study. Hepatol 1997; 25(6): 1351-60.

  22. Stauch S, Kircheis G, Adler G, Beckh K, Ditschuneit H, Gortelmeyer R, Hendricks R, Heuser A, Karoff C, Malfertheiner P, Mayer D, Rosch W, Steffens J. Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study. J Hepatol 1998; 28(5): 856-64.

  23. Rees CJ, Oppong K, Mardini H, Hudson M, Record C. Effect of L-ornithine-L-aspartate on patients with and without TIPS undergoing glutamine challenge: a double blind, placebo controlled trial. Gut 2000; 47(4): 571-574.

  24. Chen MF, Li RC, Chen CH, Gao XC. Therapeutic effect of Lornithine-L-aspartate on liver cirrhosis complicated by hepatic encephalopathy. Di Yi Jun Yi Da Xue Xue Bao 2005; 25(6): 718-9, 722. Chinese.

  25. Reddy KR, Hoofnagle JH, Tong MJ, Lee WM, Pockros P, Heathcote EJ, et al. Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group. Hepatology 1999; 30: 787-793.

  26. Nguyen MH, Whittemore AS, Garcia RT, Tawkeek SA, Ning J, Lam S, et al. Role of ethnicity in risk for hepatocellular carcinoma in patients with chronic hepatitis C and cirrhosis. Clin Gastroenterol Hepatol 2004; 2: 820-824.

  27. Nair S, Eustace J, Thuluvath PJ. Effect of race on outcome of orthotopic liver transplantation: a cohort study. Lancet 2002; 359: 287-293.

  28. Conn HO. Trailmaking and number connection test in the assessment of mental state in portal systemic encephalopathy. Am J Dig Dis 1977; 22: 541-50.

  29. Uribe M, Marquez MA, Garcia Ramos G, Ramos-Uribe MH, et al. Treatment of chronic portal-systemic encephalopathy with vegetable and animal protein diets. A controlled crossover study. Dig Dis Sci 1982; 27(12): 1109-1116.

  30. Ratcliffe J, Longworth L, Young T, Bryan S, Burroughs A, Buxton M. Cost-Effectiveness of Liver Transplantation Team. Assessing health-related quality of life pre- and post-liver transplantation: a prospective multicenter study. Liver Transpl 2002; 8(3): 263-70.

  31. Dawson B, Trapp R. Basic & Clinical Biostatistics. 3rd. Edition. Mc Graw Hill. USA, 2001.

  32. Cordoba J, Lopez-Hellin J, Planas M, et al. Normal protein diet for episodic hepatic encephalopathy: results of a randomized study. J Hepatol 2004; 41: 38-43.

  33. Mans M, DeJoseph R, Hawkins R. Metabolic abnormalities and grade of encephalopathy in acute hepatic failure. Journal of Neurochemistry 1994; 63: 1829-1838.

  34. Talwalkar J, Kamath P. Influence of recent advances in medical management on clinical outcomes of cirrhosis. Mayo Clinic Proc 2005; 80(11): 1501-1508.




2020     |     www.medigraphic.com